A phase IIb study of extended-release formulation of SPN-812 in patients with attention deficit hyperactivity disorder (ADHD)

Trial Profile

A phase IIb study of extended-release formulation of SPN-812 in patients with attention deficit hyperactivity disorder (ADHD)

Completed
Phase of Trial: Phase II

Latest Information Update: 09 May 2017

At a glance

  • Drugs Viloxazine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Sponsors Supernus Pharmaceuticals
  • Most Recent Events

    • 09 May 2017 According to a Supernus Pharmaceuticals media release, company is on track to meet with the FDA in the second quarter of 2017 for an end-of-Phase II meeting.
    • 04 May 2017 Status changed from active, no longer recruiting to completed.
    • 02 Aug 2016 According to a Supernus Pharmaceuticals media release, status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top